<DOC>
	<DOCNO>NCT00680017</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy combination ABT-335 plus rosuvastatin dyslipidemic subject Chronic Kidney Disease ( CKD ) Stage 3 .</brief_summary>
	<brief_title>30 Week Study Combination ABT-335 Rosuvastatin Compared Rosuvastatin Monotherapy Subjects With Dyslipidemia Stage 3 Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Inclusion Criteria Dyslipidemic participant Chronic Kidney Disease Stage 3 For entry Treatment Phase ( Visit 3 ) , participant satisfy follow laboratory criterion ( measure Screening Visit [ ] ) : Estimated glomerular filtration rate 30 59 mL/min/1.73 m2 ( Chronic Kidney Disease Stage 3 ) simplify 4 variable Modification Diet Renal Disease formula ( include 10 percent variation upper limit estimate glomerular filtration rate allow enrollment participant account variability creatinine assay ) . Fasting lipid result follow great equal 12hour fasting period : Triglycerides level great equal 150 mg/dL , Highdensity lipoprotein cholesterol le 40 mg/dL male less 50 mg/dL female , Lowdensity lipoprotein cholesterol great equal 130 mg/dL Exclusion Criteria Participants certain chronic unstable medical condition . Participants unstable dose medication receive coumarin anticoagulant , systemic cyclosporine , certain medication . Pregnant lactate woman , woman intend become pregnant . Participants diabetes mellitus poorly control . Participants Asian ancestry ( Filipino , Chinese , Japanese , Korean , Vietnamese , AsianIndian origin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Dyslipidemia</keyword>
	<keyword>Kidney Disease</keyword>
</DOC>